EA201301111A1 - ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ - Google Patents

ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ

Info

Publication number
EA201301111A1
EA201301111A1 EA201301111A EA201301111A EA201301111A1 EA 201301111 A1 EA201301111 A1 EA 201301111A1 EA 201301111 A EA201301111 A EA 201301111A EA 201301111 A EA201301111 A EA 201301111A EA 201301111 A1 EA201301111 A1 EA 201301111A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
thieno
arrhythmia
pyrimidine derivatives
compounds
Prior art date
Application number
EA201301111A
Other languages
English (en)
Inventor
Дерек Эдуард Джон
Джон Форд
Original Assignee
Зеншен Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301111(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зеншен Лимитед filed Critical Зеншен Лимитед
Publication of EA201301111A1 publication Critical patent/EA201301111A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к тиенопиримидиновым соединениям, которые являются ингибиторами калиевого канала. Также описаны фармацевтические композиции, которые содержат соединения, и их применение для лечения аритмии.
EA201301111A 2011-04-01 2012-03-29 ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ EA201301111A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (en) 2011-04-01 2012-03-29 Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia

Publications (1)

Publication Number Publication Date
EA201301111A1 true EA201301111A1 (ru) 2014-02-28

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301111A EA201301111A1 (ru) 2011-04-01 2012-03-29 ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ

Country Status (42)

Country Link
US (1) US9249155B2 (ru)
EP (1) EP2694518B1 (ru)
JP (1) JP5826374B2 (ru)
KR (1) KR20140023332A (ru)
CN (1) CN103492392B (ru)
AP (1) AP2013007198A0 (ru)
AR (1) AR088735A1 (ru)
AU (1) AU2012235882B2 (ru)
BR (1) BR112013025236A2 (ru)
CA (1) CA2831493A1 (ru)
CL (1) CL2013002789A1 (ru)
CO (1) CO6801756A2 (ru)
CR (1) CR20130488A (ru)
CU (1) CU24173B1 (ru)
CY (1) CY1117025T1 (ru)
DK (1) DK2694518T3 (ru)
EA (1) EA201301111A1 (ru)
EC (1) ECSP13012988A (ru)
ES (1) ES2558563T3 (ru)
GB (1) GB201105659D0 (ru)
GT (1) GT201300225A (ru)
HK (2) HK1193096A1 (ru)
HR (1) HRP20151340T1 (ru)
HU (1) HUE028438T2 (ru)
IL (1) IL228555A0 (ru)
MA (1) MA35064B1 (ru)
ME (1) ME02314B (ru)
MX (1) MX335937B (ru)
NI (1) NI201300100A (ru)
PE (1) PE20141021A1 (ru)
PL (1) PL2694518T3 (ru)
PT (1) PT2694518E (ru)
RS (1) RS54458B1 (ru)
RU (1) RU2013148627A (ru)
SG (1) SG193578A1 (ru)
SI (1) SI2694518T1 (ru)
SM (1) SMT201500322B (ru)
TN (1) TN2013000377A1 (ru)
TW (1) TWI516265B (ru)
UA (1) UA110131C2 (ru)
WO (1) WO2012131379A1 (ru)
ZA (1) ZA201307085B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078957A1 (en) * 2012-11-20 2014-05-30 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
BR112018012914B1 (pt) 2015-12-22 2023-04-18 SHY Therapeutics LLC Composto, uso de um composto e composição farmacêutica
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
IL271230B1 (en) 2017-06-21 2024-02-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
WO1997007119A1 (en) 1994-08-26 1997-02-27 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
CN1226243A (zh) 1996-07-26 1999-08-18 日产化学工业株式会社 苯并二氢吡喃衍生物
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
JP2002517385A (ja) 1998-06-05 2002-06-18 イカゲン インク． カリウムチャネル阻害剤
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
WO2001021610A1 (en) 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
AU7319800A (en) 1999-09-24 2001-04-24 Nissan Chemical Industries Ltd. 4-oxybenzopyran derivative
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
US6677371B1 (en) 1999-10-05 2004-01-13 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
EP1240147A1 (en) 1999-12-21 2002-09-18 Icagen, Inc. Potassium channel inhibitors
CA2421819C (en) 2000-09-20 2010-03-09 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US20040063731A1 (en) 2001-02-02 2004-04-01 Hans-Michael Eggenweiler Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE60206505T2 (de) 2001-06-25 2006-07-06 Nissan Chemical Industries, Ltd. Substituierte benzopyranderivate gegen arrhytmie
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
DE602004020070D1 (de) * 2003-06-11 2010-10-07 Xention Ltd Thienopyrimidin-derivate als kaliumkanal-inhibitoren
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
WO2005066182A1 (en) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
EP1768986A2 (en) 2004-06-29 2007-04-04 Amgen Inc. Furanopyrimidines
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
JP5173429B2 (ja) 2004-12-09 2013-04-03 ゼンション・リミテッド 化合物
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
CA2654842A1 (en) * 2006-06-12 2007-12-21 Vertex Pharmaceuticals Incorporated Thienopyrimidines useful as modulators of ion channels
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
CY1117025T1 (el) 2017-04-05
WO2012131379A1 (en) 2012-10-04
TW201244720A (en) 2012-11-16
CL2013002789A1 (es) 2014-07-18
CA2831493A1 (en) 2012-10-04
MA35064B1 (fr) 2014-04-03
JP2014509637A (ja) 2014-04-21
SI2694518T1 (sl) 2016-02-29
TWI516265B (zh) 2016-01-11
BR112013025236A2 (pt) 2019-09-24
CO6801756A2 (es) 2013-11-29
AU2012235882A1 (en) 2013-05-02
AU2012235882B2 (en) 2015-08-06
US20140206703A1 (en) 2014-07-24
CU24173B1 (es) 2016-04-25
HK1193096A1 (zh) 2014-09-12
ME02314B (me) 2016-06-20
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
DK2694518T3 (en) 2015-11-09
PT2694518E (pt) 2016-02-05
CR20130488A (es) 2013-12-06
AR088735A1 (es) 2014-07-02
NI201300100A (es) 2014-01-07
HUE028438T2 (en) 2017-02-28
CN103492392B (zh) 2015-11-25
PL2694518T3 (pl) 2016-03-31
MX335937B (es) 2016-01-04
UA110131C2 (ru) 2015-11-25
SG193578A1 (en) 2013-10-30
EP2694518B1 (en) 2015-10-07
GB201105659D0 (en) 2011-05-18
IL228555A0 (en) 2013-12-31
ES2558563T3 (es) 2016-02-05
KR20140023332A (ko) 2014-02-26
JP5826374B2 (ja) 2015-12-02
CU20130124A7 (es) 2014-01-29
GT201300225A (es) 2014-12-30
AP2013007198A0 (en) 2013-10-31
EP2694518A1 (en) 2014-02-12
RS54458B1 (en) 2016-06-30
US9249155B2 (en) 2016-02-02
NZ615621A (en) 2015-01-30
PE20141021A1 (es) 2014-08-30
MX2013011301A (es) 2014-04-16
HK1193806A1 (zh) 2014-10-03
ZA201307085B (en) 2015-04-29
SMT201500322B (it) 2016-02-25
HRP20151340T1 (hr) 2016-02-26
ECSP13012988A (es) 2013-12-31
CN103492392A (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
NZ700928A (en) Dna-pk inhibitors
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
EA201492204A1 (ru) Нуклеозиды на основе урацила и спирооксетана
MY177344A (en) Compounds and their methods of use
EA201890333A1 (ru) Противовирусные соединения
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
EA201590879A1 (ru) Арилконденсированные и гетероарилконденсированные лактамы
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
MD20140136A2 (ru) Ингибиторы вируса гепатита С
IN2014CN04530A (ru)
EA201492002A1 (ru) Противовирусные соединения
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201491376A1 (ru) Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201490223A1 (ru) Составы на основе дарунавира
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ